Focus on prostate cancer

Cancer Cell

Volumn 2, Issue 2, 2002, Pages 113-116

  Isaacs, William ^a   De Marzo, Angelo ^a   Nelson, William G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANTIBODY; GLUTATHIONE TRANSFERASE; PROSTATE SPECIFIC ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROSTATE STEM CELL ANTIGEN ANTIBODY; UNCLASSIFIED DRUG;

ANDROGEN ABLATION THERAPY; ANDROGEN THERAPY; ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER STAGING; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOME MUTATION; DISEASE COURSE; DISEASE MARKER; FAMILIAL CANCER; FAMILY HISTORY; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HORMONE DEPENDENCE; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; REVIEW; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; PROSTATE TUMOR;

ANDROGENS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 0012510076     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00103-4     Document Type: Article

References (31)

1. Bastacky, S.I., Wojno, K.J., Walsh, P.C., Carmichael, M.J., and Epstein, J.I. (1995). Pathological features of hereditary prostate cancer. J. Urol. 153, 987-992.
2. Berges, R.R., Vukanovic, J., Epstein, J.I., CarMichel, M., Cisek, L., Johnson, D.E., Veltri, R.W., Walsh, P.C., and Isaacs, J.T. (1995). Implication of cell kinetic changes during the progression of human prostatic cancer. Clin. Cancer Res. 1, 473-480.
3. Boring, C.C., Squires, T.S., and Tong, T. (1992). Cancer statistics, 1992. CA Cancer J. Clin. 42, 19-38.
4. Bostwick, D.G. (1989). Prostatic intraepithelial neoplasia (PIN). Urology 34, 16-22.
5. Bunting, P.S. (2002). Screening for prostate cancer with prostate-specific antigen: beware the biases. Clin. Chim. Acta 315, 71-97.
6. Carpten, J., Nupponen, N., Isaacs, S., Sood, R., Robbins, C., Xu, J., Faruque, M., Moses, T., Ewing, C., Gillanders, E., et al. (2002). Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat. Genet. 30, 181-184.
7. Chan, J.M., Stampfer, M.J., Giovannucci, E., Gann, P.H., Ma, J., Wilkinson, P., Hennekens, C.H., and Pollak, M. (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279, 563-566.
8. Chen, C.D., and Sawyers, C.L. (2002). NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol. Cell. Biol. 22, 2862-2870.
9. Chesire, D.R., Ewing, C.M., Gage, W.R., and Isaacs, W.B. (2002). In vitro evidence for complex modes of nuclear beta-catenin signaling during prostate growth and tumorigenesis. Oncogene 21, 2679-2694.
10. De Marzo, A.M., Putzi, M.J., and Nelson, W.G. (2001). New concepts in the pathology of prostatic epithelial carcinogenesis. Urology 57, 103-114.
11. Denmeade, S.R., Nagy, A., Gao, J., Lilja, H., Schally, A.V., and Isaacs, J.T. (1998). Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. 58, 2537-2540.
12. Fang, J., Metter, E.J., Landis, P., Chan, D.W., Morrell, C.H., and Carter, H.B. (2001). Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58, 411-416.
13. Feldman, B.J., and Feldman, D. (2001). The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1, 34-45.
14. Gong, M.C., Chang, S.S., Sadelain, M., Bander, N.H., and Heston, W.D. (1999). Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer Metastasis Rev. 18, 483-490.
15. Hsing, A.W., and Devesa, S.S. (2001). Trends and patterns of prostate cancer: what do they suggest? Epidemiol. Rev. 23, 3-13.
16. Isaacs, W., and Kainu, T. (2001 ). Oncogenes and tumor suppressor genes in prostate cancer. Epidemiol. Rev. 23, 36-41.
17. Jiang, Z., Woda, B.A., Rock, K.L., Xu, Y., Savas, L., Khan, A., Pihan, G., Cai, F., Babcook, J.S., Rathanaswami, P., et al. (2001). P504S: a new molecular marker for the detection of prostate carcinoma. Am. J. Surg. Pathol. 25, 1397-1404.
18. McNeal, J.E. (1978). Origin and evolution of benign prostatic enlargement. Invest Urol. 15, 340-345.
19. Narla, G., Heath, K.E., Reeves, H.L., Li, D., Giono, L.E., Kimmelman, A.C., Glucksman, M.J., Narla, J., Eng, R.J., Chan, A.M., et al. (2001). KLR6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294, 2563-2566.
20. Nelson, W.G., De Marzo, A.M., Deweese, T.L., Lin, X., Brooks, J.D., Putzi, M.J., Nelson, C.P., Groopman, J.D., and Kensler, T.W. (2001). Preneoplastic prostate lesions: an opportunity for prostate cancer prevention. Ann. N Y Acad. Sci. 952, 135-144.
21. Neshat, M.S., Mellinghoff, I.K., Tran, C., Stiles, B., Thomas, G., Petersen, R., Frost, P., Gibbons, J.J., Wu, H., and Sawyers, C.L. (2001). Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98, 10314-10319.
22. Pound, C.R., Partin, A.W., Eisenberger, M.A., Chan, D.W., Pearson, J.D., and Walsh, P.C. (1999). Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281, 1591-1597.
23. Rodriguez, R., Schuur, E.R., Lim, H.Y., Henderson, G.A., Simons, J.W., and Henderson, D.R. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559-2563.
24. Ross, R.K., Pike, M.C., Coetzee, G.A., Reichardt, J.K., Yu, M.C., Feigelson, H., Stanczyk, F.Z., Kolonel, L.N., and Henderson, B.E. (1998). Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res. 58, 4497-4504.
25. Saffran, D.C., Raitano, A.B., Hubert, R.S., Witte, O.N., Reiter, R.E., and Jakobovits, A. (2001). Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts. Proc. Natl. Acad. Sci. USA 98, 2658-2663.
26. Singh, D., Febbo, P.G., Ross, K., Jackson, D.G., Manola, J., Ladd, C., Tamayo, P., Renshaw, A.A., D'Amico, A.V., Richie, J.P., et al. (2002). Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 1, 203-209.
27. Stanford, J.L., and Ostrander, E.A. (2001). Familial prostate cancer. Epidemiol. Rev. 23, 19-23.
28. Stanford, J.L., Stephenson, R.A., Coyle, L.M., Cerhan, J., Correa, R., Eley, J.W., Gilliland, F., Hankey, B., Kolonel, L.N., Kosary, C., et al. (1999). Prostate Cancer Trends 1973-1995, SEER Program, National Cancer Institute NIH Pub No 99-4543 (Bethesda, MD)
29. Tavtigian, S.V., Simard, J., Teng, D.H., Abtin, V., Baumgard, M., Beck, A., Camp, N.J., Carillo, A.R., Chen, Y., Dayananth, P., et al. (2001). A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet. 27, 172-180.
30. Truica, C.I., Byers, S., and Gelmann, E.P. (2000). Beta-catenin affects androgen receptor transcriptional activity and ligand specificity. Cancer Res. 60, 4709-4713.
31. Xu, J. (2000). Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. Am. J. Hum. Genet. 66, 945-957.